Washington, D.C. 20549

                                  FORM 8-K

                               CURRENT REPORT
                   Pursuant to Section 13 or 15(d) of the
                      Securities Exchange Act of 1934

             Date of Report (Date of Earliest Event Reported):
                   November 20, 2001 (November 19, 2001)

           (Exact name of registrant as specified in its charter)

DELAWARE                         39040                      13-4022871
(State or other        (Commission File Number)           (I.R.S. Employer
jurisdiction of                                          Identification No.)

100 Painters Drive
Chadds Ford, Pennsylvania                                      19317
(Address of principal executive offices)                    (Zip Code)

                               (610) 558-9800
            (Registrant's telephone number, including area code)

       (Former name or former address, if changed since last report)

Item 7.  Financial Statements and Exhibits.

(a)      Financial Statements of Business Acquired.

                  Not applicable.

(b)      Pro Forma Financial Information.

                  Not applicable.

(c)      Exhibits.

Exhibit Number             Description

       99.1                Press release issued by Endo Pharmaceuticals
                           Holdings Inc. on November 19, 2001

Item 9.  Regulation FD Disclosure.

         On November 19, 2001, the Registrant issued a press release, a
copy of which is filed herewith as Exhibit 99.1 and is incorporated herein
by reference.


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

                                    ENDO PHARMACEUTICALS HOLDINGS INC.

                                    By:   /s/ CAROL A. AMMON
                                        Name: Carol A. Ammon
                                        Title: President & Chief Executive

Dated:  November 20, 2001

                             INDEX TO EXHIBITS

Exhibit No.                         Description

       99.1                Press release issued by Endo Pharmaceuticals
                           Holdings Inc. on November 19, 2001

                                                               Exhibit 99.1

Contact: Robert Siegfried/Jeremy Fielding
Kekst and Company


            Chadds Ford, PA, November 19, 2001 - Endo Pharmaceuticals
Holdings Inc. (NASDAQ: ENDP and ENDPW) announced today that it had closed
the sale of an additional 1,525,000 shares of common stock, at $8.00 per
share, issued by the Company in connection with the exercise by the
underwriters in the Company's recent public offering of their
over-allotment option. The recent public offering was underwritten through
an underwriting syndicate led by JP Morgan and Salomon Smith Barney,
together with co-managers, SG Cowen and Wachovia Securities. Including the
shares issued today, a total of 12,925,000 shares common stock were issued
and sold by the Company in this transaction.

            Endo, through its wholly owned subsidiaries Endo
Pharmaceuticals Inc. and Endo Inc., is a fully integrated specialty
pharmaceutical company with market leadership in pain management. The
company is engaged in the research, development, sales and marketing of
both branded and generic pharmaceutical products primarily for the
treatment of pain.

            A registration statement relating to these securities has been
declared effective by the Securities and Exchange Commission. This
communication shall not constitute an offer to sell or the solicitation of
an offer to buy any of these securities. A Prospectus relating to these
securities may be obtained from JP Morgan at 60 Wall Street, New York, NY
10260 or Salomon Smith Barney at 388 Greenwich Street, 32nd Floor, New
York, NY 10013.